Pharmacology, Toxicology and Pharmaceutical Science
Adalimumab
8%
Ankylosing Spondylitis
5%
Biological Product
18%
Disease
15%
Disease Activity
14%
Disease Modifying Antirheumatic Drug
32%
Etanercept
13%
Infection
15%
Inflammatory Arthritis
5%
Infliximab
11%
Interstitial Lung Disease
5%
Juvenile Rheumatoid Arthritis
5%
Malignant Neoplasm
8%
Methotrexate
6%
Necrosis
5%
Observational Study
13%
Psoriatic Arthritis
14%
Remission
6%
Rheumatoid Arthritis
100%
Rituximab
11%
Standardized Incidence Ratio
5%
Tocilizumab
6%
Tumor Necrosis
28%
Tumor Necrosis Factor
45%
Tumor Necrosis Factor Inhibitor
31%
Medicine and Dentistry
Biological Product
23%
Biological Therapy
5%
DAS28
11%
Disease Activity
10%
Disease Modifying Antirheumatic Drug
24%
Disease-Modifying Antirheumatic Drug
9%
Diseases
8%
Etanercept
10%
Hazard Ratio
5%
Health Assessment Questionnaire
8%
Infection
6%
Infliximab
8%
Interstitial Lung Disease
5%
Juvenile Idiopathic Arthritis
5%
Low Back Pain
5%
Malignant Neoplasm
9%
Methotrexate
6%
Necrosis
6%
Observational Study
10%
Population
7%
Psoriatic Arthritis
8%
Rheumatoid Arthritis
87%
Rituximab
11%
Standardized Incidence Ratio
6%
TNF Inhibitor
24%
Tocilizumab
5%
Tumor Necrosis
20%
Tumor Necrosis Factor
40%
Nursing and Health Professions
Biological Product
9%
Biosimilar Agent
5%
Disease
6%
Disease Modifying Antirheumatic Drug
7%
Etanercept
8%
Health Assessment Questionnaire
5%
Infection
6%
Juvenile Rheumatoid Arthritis
5%
Low Back Pain
5%
Rheumatoid Arthritis
30%
Rituximab
11%
Tumor Necrosis Factor
14%
Tumor Necrosis Factor Inhibitor
11%